CYTKNasdaqPharmaceutical PreparationsFiscal year ends December 31
CYTOKINETICS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$62.65+0.70 (+1.13%)
Close on Oct 19, 2026
- Market cap
- $8.28M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$4.21 (+7.20%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
CYTOKINETICS INC saw revenue fall 21.1% to $67.67M over the twelve months to Jun 30, 2026. Free cash flow was -$580.72M.
Revenue
$67.67M
-21.1% vs. a year earlier
Operating income
-$707.91M
TTM Q2 2026
Free cash flow
-$580.72M
TTM Q2 2026
EPS, diluted
-$6.54
FY2025
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $8.28M
- P/E ratio
- –
- Price to sales
- 0.12
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -7017.54%
Fundamentals
- Revenue
- $67.67M
- Net income
- -$894.00M
- EPS, diluted
- -$6.54
- Free cash flow
- -$580.72M
- Book value per share
- -$1313.44
- Diluted shares
- 0M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$67.67M-21.1% YoY
Operating income
-$707.91M
Net income
-$894.00M
EPS, diluted
–
Free cash flow
-$580.72M
Reported periodTrailing twelve months